RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Monthly Archives: June 2010
Cato at the Cancer Vaccines Meeting
This week, Cato Research is attending the Cancer Vaccines meeting in Cambridge, MA on 29 and 30 June. The conference is the first meeting dedicated to progressing cancer vaccines to market and will feature 21 of the world’s leading experts … Continue reading
Posted in Conferences and Meetings
Tagged cancer, Chemotherapy, clinical trials, immune system, monoclonal antibody therapy, pancreatic cancer, vaccines
Comments Off
Novel Approaches to Clinical Trial Recruitment
Traditional patient recruitment strategies like print, television and radio ads are relatively expensive and much less effective than targeted online advertisement. Eighty percent of Americans who are online are now searching for health information (Allison, 2009), including avenues to participate … Continue reading
Posted in Clinical Trials, Social Media
Tagged clinical trials, CROs, Facebook, FDA, Google, multiple sclerosis, MySpace, patient recruitment, Social Media, Twitter, Yahoo
Comments Off
FDA Begins Releasing Safety Analyses of Recently Approved Products
The safety of the people shall be the highest law. – Marcus Tullius Cicero Evaluating drug safety is, as I’m sure you know, always an exercise in measuring risks and benefits. One question that can haunt the dreams of companies … Continue reading
Posted in Clinical Trials, FDA, Industry News
Tagged clinical trials, FDA, FDAAA, postmarketing
Comments Off
Adaptive Designs and Clinical Supplies
In a recent post, John Johnson discussed the FDA’s draft guidance on Adaptive Design Clinical Trials for Drugs and Biologics, particularly in the context of planning and designing a clinical trial. My perspective concerns challenges related to clinical supplies (CS) … Continue reading
Posted in Clinical Trials
Tagged adaptive design, adaptive trials, analytical testing, API, clinical supplies, clinical trials, drug product, FDA, guidance, labeling, manufacturing
1 Comment
